A Monocentric, Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Nitazoxanide at 500mg Twice Daily on Collagen Turnover in Plasma in NASH Patients With Fibrosis Stage 2 or 3
Phase: PHASE2
Conditions: Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Sponsor: Pinnacle Clinical Research, PLLC

Protocol 
 
A Monocentric, Open-Label, Proof of Concept Study to Evaluate the 
Safety and Efficacy of NTZ at 500mg Twice Daily on Collagen Turnover 
in Plasma in NASH Patients with Fibrosis Stage 2 or 3. 
 
 
NCT Number: 03656068 
Unique Protocol ID: NTZ-218-1 
Version Date : 02 March 2019